Acadia Pharmaceuticals names Jonathan Poole to board of directors

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) appointed Jonathan M. Poole to its board of directors, effective March 3, 2026, according to a company statement. Poole will serve on the company's audit committee.

Poole currently serves as senior vice president of finance at Vertex Pharmaceuticals, Inc., a position he has held since March 2020. In that role, he has led the global finance team during portfolio expansion and commercial growth, including multiple acquisitions.

Prior to Vertex, Poole served as chief financial officer of Evelo Biosciences, Inc. from March 2018 to March 2020, and as CFO of Genocea Biosciences, Inc. from April 2014 to March 2018. He also served as a director of Codiak Biosciences, Inc. from July 2018 through March 2020, where he chaired the audit committee.

Poole holds a bachelor's degree in biological sciences from Durham University in the United Kingdom and an MBA from London Business School.

Stephen R. Biggar, chairman of Acadia's board of directors, said Poole's appointment strengthens the board's financial and operational expertise as the company executes its growth strategy.

Acadia Pharmaceuticals develops treatments for neurological and rare diseases. The company's commercial portfolio includes treatments for Parkinson's disease psychosis and Rett syndrome.

You May Also Be Interested In

• Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
• Newmont names ex-BHP finance chief Peter Beaven to its board
• NorthStrive files two patents for muscle-loss drugs in spaceflight